DKK 198.95
(2.82%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 14.35 Billion DKK | 15.83% |
2022 | 12.39 Billion DKK | 2.5% |
2021 | 12.08 Billion DKK | 38.02% |
2020 | 8.75 Billion DKK | 24.29% |
2019 | 7.04 Billion DKK | 130.23% |
2018 | 3.06 Billion DKK | -2.91% |
2017 | 3.15 Billion DKK | 11.65% |
2016 | 2.82 Billion DKK | 41.95% |
2015 | 1.98 Billion DKK | 5.4% |
2014 | 1.88 Billion DKK | 29.96% |
2013 | 1.45 Billion DKK | -5.65% |
2012 | 1.53 Billion DKK | -22.13% |
2011 | 1.97 Billion DKK | 34.72% |
2010 | 1.46 Billion DKK | 15.42% |
2009 | 1.27 Billion DKK | -24.98% |
2008 | 1.69 Billion DKK | -2.18% |
2007 | 1.73 Billion DKK | 81.48% |
2006 | 954.42 Million DKK | 2.78% |
2005 | 928.56 Million DKK | 54.22% |
2004 | 602.1 Million DKK | 40.29% |
2003 | 429.16 Million DKK | 35.09% |
2002 | 317.7 Million DKK | 413.46% |
2001 | 61.87 Million DKK | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 14.27 Billion DKK | 4.8% |
2024 Q1 | 13.62 Billion DKK | -5.1% |
2023 Q4 | 14.35 Billion DKK | 7.12% |
2023 Q2 | 14.99 Billion DKK | 13.75% |
2023 Q1 | 13.18 Billion DKK | 6.37% |
2023 FY | 14.35 Billion DKK | 15.83% |
2023 Q3 | 13.39 Billion DKK | -10.63% |
2022 Q1 | 11.99 Billion DKK | -0.81% |
2022 FY | 12.39 Billion DKK | 2.5% |
2022 Q4 | 12.39 Billion DKK | 0.78% |
2022 Q3 | 12.29 Billion DKK | 2.22% |
2022 Q2 | 12.02 Billion DKK | 0.31% |
2021 Q3 | 10.11 Billion DKK | 1.09% |
2021 Q1 | 9.74 Billion DKK | 11.3% |
2021 Q2 | 10 Billion DKK | 2.67% |
2021 FY | 12.08 Billion DKK | 38.02% |
2021 Q4 | 12.08 Billion DKK | 19.49% |
2020 Q4 | 8.75 Billion DKK | -7.32% |
2020 FY | 8.75 Billion DKK | 24.29% |
2020 Q1 | 9 Billion DKK | 27.79% |
2020 Q2 | 9.24 Billion DKK | 2.64% |
2020 Q3 | 9.45 Billion DKK | 2.26% |
2019 Q2 | 2.67 Billion DKK | -3.25% |
2019 Q4 | 7.04 Billion DKK | 174.93% |
2019 Q3 | 2.56 Billion DKK | -4.07% |
2019 FY | 7.04 Billion DKK | 130.23% |
2019 Q1 | 2.76 Billion DKK | -9.77% |
2018 Q1 | 3.02 Billion DKK | -3.9% |
2018 Q3 | 3.1 Billion DKK | -1.66% |
2018 Q4 | 3.06 Billion DKK | -1.37% |
2018 FY | 3.06 Billion DKK | -2.91% |
2018 Q2 | 3.15 Billion DKK | 4.15% |
2017 Q2 | 3.06 Billion DKK | 6.48% |
2017 Q4 | 3.15 Billion DKK | 8.11% |
2017 FY | 3.15 Billion DKK | 11.65% |
2017 Q1 | 2.88 Billion DKK | 2.05% |
2017 Q3 | 2.91 Billion DKK | -4.95% |
2016 Q3 | 2.58 Billion DKK | 4.08% |
2016 FY | 2.82 Billion DKK | 41.95% |
2016 Q4 | 2.82 Billion DKK | 9.32% |
2016 Q2 | 2.48 Billion DKK | 33.24% |
2016 Q1 | 1.86 Billion DKK | -6.37% |
2015 Q4 | 1.98 Billion DKK | -7.01% |
2015 Q1 | 2.46 Billion DKK | 30.55% |
2015 Q2 | 2.22 Billion DKK | -9.87% |
2015 FY | 1.98 Billion DKK | 5.4% |
2015 Q3 | 2.13 Billion DKK | -3.67% |
2014 FY | 1.88 Billion DKK | 29.96% |
2014 Q1 | 1.33 Billion DKK | -8.25% |
2014 Q2 | 1.25 Billion DKK | -5.79% |
2014 Q3 | 1.26 Billion DKK | 0.69% |
2014 Q4 | 1.88 Billion DKK | 49.33% |
2013 Q3 | 1.45 Billion DKK | -2.88% |
2013 FY | 1.45 Billion DKK | -5.65% |
2013 Q1 | 1.38 Billion DKK | -9.74% |
2013 Q2 | 1.49 Billion DKK | 7.8% |
2013 Q4 | 1.45 Billion DKK | -0.15% |
2012 Q1 | 1.88 Billion DKK | -4.59% |
2012 Q4 | 1.53 Billion DKK | -6.38% |
2012 Q3 | 1.64 Billion DKK | -2.68% |
2012 FY | 1.53 Billion DKK | -22.13% |
2012 Q2 | 1.68 Billion DKK | -10.42% |
2011 Q2 | 1.94 Billion DKK | 40.89% |
2011 Q1 | 1.37 Billion DKK | -6.14% |
2011 Q4 | 1.97 Billion DKK | 7.27% |
2011 Q3 | 1.84 Billion DKK | -5.03% |
2011 FY | 1.97 Billion DKK | 34.72% |
2010 Q1 | 1.44 Billion DKK | 13.47% |
2010 Q4 | 1.46 Billion DKK | 7.04% |
2010 Q3 | 1.37 Billion DKK | -12.17% |
2010 FY | 1.46 Billion DKK | 15.42% |
2010 Q2 | 1.56 Billion DKK | 8.2% |
2009 Q4 | 1.27 Billion DKK | 0.0% |
2009 FY | 1.27 Billion DKK | -24.98% |
2008 FY | 1.69 Billion DKK | -2.18% |
2007 FY | 1.73 Billion DKK | 81.48% |
2006 FY | 954.42 Million DKK | 2.78% |
2005 FY | 928.56 Million DKK | 54.22% |
2004 FY | 602.1 Million DKK | 40.29% |
2003 FY | 429.16 Million DKK | 35.09% |
2002 FY | 317.7 Million DKK | 413.46% |
2001 FY | 61.87 Million DKK | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
ALK-Abelló A/S | 6.72 Billion DKK | -113.399% |
Genmab A/S | 35.28 Billion DKK | 59.327% |
Gubra A/S | 625.28 Million DKK | -2195.486% |
Novo Nordisk A/S | 314.48 Billion DKK | 95.436% |
Orphazyme A/S | 19.31 Million DKK | -74222.768% |
Pharma Equity Group A/S | 81.33 Million DKK | -17547.031% |
Zealand Pharma A/S | 3.19 Billion DKK | -348.696% |